COYA's net losses increased 43% to $21.2M despite revenue more than doubling, indicating accelerating cash burn as clinical operations expand.
The company is progressing with its ALSTARS Phase 2 trial for ALS treatment, but the substantial increase in losses alongside higher liabilities suggests mounting operational costs are outpacing revenue growth. While cash position remains strong at $46.8M, the widening accumulated deficit to $62.0M and deteriorating loss trajectory warrant close monitoring of burn rate sustainability.
COYA showed mixed financial performance with revenue surging 124% to $7.9M, but this was overshadowed by net losses jumping 43% to $21.2M and operating losses increasing 31% to $22.6M. The balance sheet remains relatively healthy with cash growing 22% to $46.8M and total assets up 13% to $50.0M, though liabilities increased 45% to $6.9M. Overall, the financial picture reflects a clinical-stage biotech scaling operations rapidly but burning cash at an accelerating pace, typical for companies advancing expensive Phase 2 trials.
Strong top-line growth of 123.6% — accelerating demand or successful expansion into new markets.
Current liabilities surged 53.5% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 45.1% — significant increase in debt or obligations, assess impact on financial flexibility.
Net income declined 42.6% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash grew 22.1% — improving liquidity position supports investment and shareholder returns.
Current assets grew 12.7% — improving short-term liquidity or inventory/receivables build.
Asset base grew 12.6% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →